Johnson & Johnson
JNJ
Get informed when a big investor buys or sells
+ FollowEarnings Call Q1 2026
April 14, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
26.2% upsideUndervalued by 26.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $560.33 Billion |
|---|---|
| Enterprise Value | $557.19 Billion |
| Dividend Yield | $5.24 (2.25%) |
| Earnings per Share | $11.03 |
| Beta | 0.26 |
| Outstanding Shares | 2,445,233,000 |
Return
| Return on Equity | 25.92% |
|---|---|
| Return on Assets | 10.47% |
| Return on Invested Capital | 17.50% |
Valuation & Multiples
| P/E Ratio | 27.05 |
|---|---|
| PEG | -51.62 |
| Price to Sales | 8.03 |
| Price to Book Ratio | 7.05 |
| Enterprise Value to Revenue | 7.67 |
| Enterprise Value to EBIT | 22.24 |
| Enterprise Value to Net Income | 26 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.23 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.8456▼ 19.42% |
|---|---|
| Total Calls | 17,492,071▲ 3.62% |
| Total Puts | 14,791,209▼ 15.74% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 72.46%▼ 3.58% |
|---|---|
| Total Invested | $431.45B▼ 1.48% |
| Investors Holding | 4,680▲ 73.00% |
ESG Score
No data
About Johnson & Johnson
CEO: Alex Gorsky At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today...
Relevant Senate Committees
This powerful committee controls taxation, trade policy, and entitlement spending (like Medicare and Medicaid pricing), all of which directly and profoundly impact JNJ's profitability, global market access, and revenue.
This committee directly allocates discretionary federal spending, including funding for health programs, medical research, and government procurement of healthcare products, directly impacting JNJ's revenue streams and market opportunities.
This committee directly regulates the FDA and NIH, which are critical for drug approval, clinical trials, and research funding – all essential to JNJ's core pharmaceutical business.
This committee's oversight of antitrust laws is critical for a large company like JNJ, and its jurisdiction over intellectual property (patents) is fundamental to the pharmaceutical industry's business model.
Hearings on drug pricing and healthcare quality for older Americans directly impact JNJ's pharmaceutical revenue, public image, and potential for regulatory scrutiny.
JNJ provides healthcare products and potentially medical devices, making it a direct beneficiary or supplier to the Department of Veterans Affairs, whose funding decisions directly impact JNJ's government contracts.